Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital trips.

Stoke Therapeutics and Biogen have dosed the first subject in the Phase III EMPEROR trial of zorevunersen for Dravet syndrome treatment.

The cancer vaccine did not significantly boost progression-free survival (PFS), but IO Biotech plans to seek out its approval anyway.

If approved, Novartis' ianalumab would become the first targeted treatment for patients with Sjögren’s disease.

In July 2025, AbbVie announced top line results from one of two parallel studies of the Phase III UP-AA trial evaluating upadacitinib in alopecia areata (AA).

After the success of the Phase Ib study, Assembly Bio’s herpes therapy will advance to Phase II trials in mid-2026.

The carefully controlled environment of a clinical trial often encounters a significant real-world challenge: concomitant medications.

Boehringer and Click's CT-155 plus antipsychotics significantly reduced negative symptoms associated with schizophrenia in a Phase III trial ...

Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

The inaugural Outsourcing in Clinical Trials & Clinical Trial Supply China conference will gather experts to discuss China's rapidly evolving clinical research landscape.

The US FDA has cleared Starlight Therapeutics' IND for a Phase Ib/IIa trial assessing the combination of STAR-001.